Global Antiemetics Market report published by Accurize Market Research forecast that the global market is expected to reach $6 billion by 2024; growing at a CAGR of 6.6% from 2017 to 2025. By geography, the Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.
Request Sample: https://www.accurizemarketresearch.com/report/global-antiemetics-market/sample-request
The rise in the number of patients suffering from cancer and an increased amount of surgical procedures in the healthcare sector to drive the growth of the market
The rise in the number of patients suffering from cancer and an increased amount of surgical procedures fuel the demand for the global antiemetic market. Furthermore, extensive research activities to revolutionize worldwide antiemetic drug therapy also boost the growth of the market.
Market Segmentation
The global antiemetics market has been bifurcated on the basis of drug class, application, and geography. The drug class segment is further segmented into cannabinoids, benzodiazepines, anticholinergics, steroids, and others. Furthermore, the application segment includes chemotherapy-induced nausea and vomiting, gastroenteritis, nausea and vomiting of pregnancy (NVP) and postoperative nausea and vomiting. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).
Request Customization: https://www.accurizemarketresearch.com/report/global-antiemetics-market/ask-for-customization
Top players in the market
The key players operational in the market includes Abbott Laboratories, AstellasPharma Inc., Aphios Corp., Aurobindo Pharma, Daiichi Sankyo Company Ltd., Eisai Co. Inc., GlaxoSmithKline Plc., Helsinn Healthcare Sa, Heron Therapeutics Inc., IPCA Laboratories Ltd., Kyowa Hakko Kirin Pharma Inc., Merck & Co. Inc., Novartis Ag, F. Hoffmann-La Roche Ag, Sanofi Aventis, Tesaro Inc. and Teva Pharmaceutical Industries Ltd., among others.
